Fluidigm (FLDM) Raised to Strong-Buy at BidaskClub

BidaskClub upgraded shares of Fluidigm (NASDAQ:FLDM) from a buy rating to a strong-buy rating in a research note issued to investors on Tuesday morning.

Other equities research analysts have also issued research reports about the stock. Piper Jaffray Companies reiterated a hold rating and set a $6.10 price objective on shares of Fluidigm in a report on Thursday, February 8th. ValuEngine lowered shares of Fluidigm from a sell rating to a strong sell rating in a report on Friday, February 2nd.

Fluidigm (NASDAQ:FLDM) traded up $0.78 during trading on Tuesday, hitting $7.97. 288,300 shares of the stock traded hands, compared to its average volume of 213,121. The company has a market cap of $277.87, a price-to-earnings ratio of -4.19 and a beta of 3.24. The company has a quick ratio of 2.46, a current ratio of 3.02 and a debt-to-equity ratio of 5.00. Fluidigm has a 12-month low of $2.52 and a 12-month high of $8.36.

Fluidigm (NASDAQ:FLDM) last released its earnings results on Thursday, February 8th. The medical research company reported ($0.27) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.25) by ($0.02). The firm had revenue of $27.75 million during the quarter, compared to the consensus estimate of $27.14 million. Fluidigm had a negative return on equity of 116.02% and a negative net margin of 59.38%. Fluidigm’s revenue was up 10.6% compared to the same quarter last year. During the same quarter last year, the business posted ($0.32) EPS. equities analysts forecast that Fluidigm will post -0.7 EPS for the current year.

In related news, insider Levin Capital Strategies, L.P. acquired 6,871 shares of the firm’s stock in a transaction that occurred on Tuesday, January 23rd. The stock was bought at an average price of $6.57 per share, for a total transaction of $45,142.47. The acquisition was disclosed in a document filed with the SEC, which is available through this link. Insiders have purchased a total of 475,744 shares of company stock valued at $2,883,151 in the last quarter. 4.70% of the stock is currently owned by company insiders.

Hedge funds and other institutional investors have recently bought and sold shares of the business. Paloma Partners Management Co purchased a new position in Fluidigm during the 4th quarter valued at about $100,000. Virtu KCG Holdings LLC purchased a new position in Fluidigm during the 2nd quarter valued at about $105,000. Sei Investments Co. increased its position in Fluidigm by 221.7% during the 3rd quarter. Sei Investments Co. now owns 21,668 shares of the medical research company’s stock valued at $109,000 after purchasing an additional 14,932 shares during the period. Group One Trading L.P. increased its position in Fluidigm by 336.9% during the 3rd quarter. Group One Trading L.P. now owns 23,155 shares of the medical research company’s stock valued at $117,000 after purchasing an additional 17,855 shares during the period. Finally, MetLife Investment Advisors LLC purchased a new position in Fluidigm during the 4th quarter valued at about $121,000. 94.79% of the stock is currently owned by institutional investors and hedge funds.

WARNING: “Fluidigm (FLDM) Raised to Strong-Buy at BidaskClub” was reported by StockNewsTimes and is owned by of StockNewsTimes. If you are viewing this news story on another publication, it was stolen and republished in violation of United States and international trademark and copyright legislation. The correct version of this news story can be viewed at https://stocknewstimes.com/2018/02/16/fluidigm-fldm-raised-to-strong-buy-at-bidaskclub.html.

About Fluidigm

Fluidigm Corporation creates, manufactures and markets technologies and life science tools focused on the exploration and analysis of single cells, as well as the industrial application of genomics, based upon the Company’s core microfluidics and mass cytometry technologies. The Company operates in the development, manufacturing and commercialization of life science tools for the life science and Ag-Bio industries segment.

Receive News & Ratings for Fluidigm Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fluidigm and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply